TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Mr. Luc Mainville to its Board of Directors. Mr. Mainville has also been appointed to the Audit Committee and will also serve as its Chair.
Mr. Mainville is currently Executive Vice President at Cardiome Pharma Corp., previously serving as President and Chief Executive Officer of Neopharm Labs Inc. and prior to that LAB Research Inc. He has gained considerable experience throughout his career in senior management and corporate finance roles, and served as a director for a number of public and private companies in the biotechnology and pharmaceutical industries. In particular, Mr. Mainville has led more than 30 mergers and acquisitions, as well as served as Chair of the Audit Committee for a number of Boards, including that of Enobia Pharma, Powertech Corporation, Cyplasin Biomedical, Alethia BioTherapeutics and Bioaxone Therapeutics. He served as Vice-Chairman of BioteCanada, and also teaches corporate governance and mergers and acquisitions courses at McGill University in Montreal, Quebec. Prior to his career in the life science industry, Mr. Mainville was a Partner at KPMG.
“We are pleased to welcome Mr. Mainville to the Acerus Board of Directors,” commented Ian Ihnatowycz, Chairman of the Board. “His demonstrated organizational and operational experience in finance, transaction and strategic planning represents a significant asset to Acerus as we move forward in the building of our business.”
Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 40 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.